scholarly journals The non-peptidic δ-opioid receptor agonist Tan-67 mediates neuroprotection post-ischemically and is associated with altered amyloid precursor protein expression, maturation and processing in mice

2017 ◽  
Vol 144 (3) ◽  
pp. 336-347 ◽  
Author(s):  
Jia-Wei Min ◽  
Yanying Liu ◽  
David Wang ◽  
Fangfang Qiao ◽  
Hongmin Wang
Keyword(s):  
Protein Expression ◽  
Amyloid Precursor Protein ◽  
Opioid Receptor ◽  
Receptor Agonist ◽  
Precursor Protein ◽  
Amyloid Precursor Protein Expression ◽  
Opioid Receptor Agonist ◽  
Δ Opioid Receptor

Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy µ opioid receptor agonist and a δ opioid receptor antagonist

2020 ◽  
Vol 237 (12) ◽  
pp. 3591-3602
Author(s):  
Sanjana Mada ◽  
Lisa R. Gerak ◽  
Amélie Soyer ◽  
David R. Maguire ◽  
Zehua Hu ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Opioid Receptor ◽  
Receptor Agonist ◽  
Behavioral Effects ◽  
Opioid Receptor Antagonist ◽  
Opioid Receptor Agonist ◽  
Δ Opioid Receptor

δ-Opioid receptor agonist SNC80 induces central antinociception mediated by Ca2+-activated Cl-channels

2012 ◽  
Vol 64 (8) ◽  
pp. 1084-1089 ◽  
Author(s):  
Daniela da Fonseca Pacheco ◽  
Cinthia Mara da Fonseca Pacheco ◽  
Igor Dimitri Gama Duarte
Keyword(s):  
Opioid Receptor ◽  
Receptor Agonist ◽  
Opioid Receptor Agonist ◽  
Cl Channels ◽  
Δ Opioid Receptor

scholarly journals Convulsant activity of a non-peptidic δ-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats

2002 ◽  
Vol 164 (1) ◽  
pp. 42-48 ◽  
Author(s):  
Daniel Broom ◽  
Emily Jutkiewicz ◽  
John Folk ◽  
John Traynor ◽  
Kenner Rice ◽  
...  
Keyword(s):  
Opioid Receptor ◽  
Receptor Agonist ◽  
Sprague Dawley ◽  
Opioid Receptor Agonist ◽  
Sprague Dawley Rats ◽  
Δ Opioid Receptor

scholarly journals Effects of RNA Splicing Inhibitors on Amyloid Precursor Protein Expression

ACS Omega ◽  
2018 ◽  
Vol 3 (3) ◽  
pp. 2798-2803 ◽  
Author(s):  
Bing Bai ◽  
Sen Wang ◽  
Yuxin Chen ◽  
Jia Jia ◽  
Xinyu Tian ◽  
...  
Keyword(s):  
Protein Expression ◽  
Amyloid Precursor Protein ◽  
Rna Splicing ◽  
Precursor Protein ◽  
Amyloid Precursor Protein Expression

Differential Effects of μ-, δ-, and κ-Opioid Receptor Agonists on Mechanosensitive Gastric Vagal Afferent Fibers in the Rat

2000 ◽  
Vol 83 (4) ◽  
pp. 2209-2216 ◽  
Author(s):  
Noriyuki Ozaki ◽  
J. N. Sengupta ◽  
G. F. Gebhart
Keyword(s):  
Opioid Receptor ◽  
Receptor Agonist ◽  
Dose Range ◽  
Receptor Agonists ◽  
Afferent Fibers ◽  
Opioid Receptor Agonist ◽  
Resting Activity ◽  
Vagal Afferent ◽  
Δ Opioid Receptor ◽  
Opioid Receptor Agonists

Single-fiber recordings were made from the decentralized right cervical vagus nerve (hyponodosal) of the rat. A total of 56 afferent fibers that responded to gastric distension (GD) were studied: 6 fibers were stimulated by phasic balloon GD, 50 by fluid GD. All fibers gave increasing responses to increasing pressures of GD (5–60 mmHg). The effects of μ-opioid (morphine), δ-opioid (SNC80), and κ-opioid (EMD61,753, U62,066) receptor agonists were tested on responses of afferent fibers to GD. Morphine, administered systemically over a broad dose range (10 μg to 31 mg/kg, cumulative), had no effect on either resting activity or responses of vagal afferent fibers to GD. Similarly, the δ-opioid receptor agonist SNC80 (0.05–3.2 mg/kg) did not affect resting activity or responses to GD. In contrast, cumulative intra-arterial doses of the κ-opioid receptor agonist EMD61,753 or U62,066 dose dependently attenuated afferent fiber responses to GD. Doses producing inhibition to 50% of the control response to GD of EMD61,753 (8.0 mg/kg) and U62,066 (8.8 mg/kg) did not differ. The effect of U62,066 was moderately attenuated by a nonselective dose (4 mg/kg) of naloxone hydrochloride; the κ-opioid receptor-selective antagonist nor-BNI (20 mg/kg) was ineffective. These results demonstrate that κ-, but not μ- or δ-opioid receptor agonists modulate visceral sensation conveyed by vagal afferent fibers innervating the stomach. Given that κ-opioid receptor agonists effects were only modestly antagonized by naloxone and not at all by nor-BNI, the results point to a novel site of action.

scholarly journals Combination of a δ-opioid Receptor Agonist and Loperamide Produces Peripherally-mediated Analgesic Synergy in Mice

2019 ◽  
Vol 131 (3) ◽  
pp. 649-663 ◽  
Author(s):  
Daniel J. Bruce ◽  
Cristina D. Peterson ◽  
Kelley F. Kitto ◽  
Eyup Akgün ◽  
Sophia Lazzaroni ◽  
...  
Keyword(s):  
Nervous System ◽  
Opioid Receptor ◽  
Receptor Agonist ◽  
Complete Freund’S Adjuvant ◽  
Opioid Receptor Agonist ◽  
The Central Nervous System ◽  
Freund’S Adjuvant ◽  
Complete Freund's Adjuvant ◽  
Freund's Adjuvant ◽  
Δ Opioid Receptor

Abstract Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New Background The long-term use of opioids for analgesia carries significant risk for tolerance, addiction, and diversion. These adverse effects are largely mediated by μ-opioid receptors in the central nervous system. Based on the authors’ previous observation that morphine and δ-opioid receptor agonists synergize in spinal cord in a protein kinase Cε–dependent manner, they predicted that this μ-opioid receptor–δ-opioid receptor synergy would take place in the central terminals of nociceptive afferent fibers and generalize to their peripheral terminals. Therefore, the authors hypothesized that loperamide, a highly efficacious μ-opioid receptor agonist that is excluded from the central nervous system, and oxymorphindole, a δ-opioid receptor agonist that was shown to synergize with morphine spinally, would synergistically reverse complete Freund’s adjuvant–induced hyperalgesia. Methods Using the Hargreaves assay for thermal nociception, the von Frey assay for mechanical nociception and the complete Freund’s adjuvant–induced model of inflammatory pain, we tested the antinociceptive and antihyperalgesic effect of loperamide, oxymorphindole, or the loperamide–oxymorphindole combination. Animals (Institute for Cancer Research [ICR] CD1 strain mice; n = 511) received drug by systemic injection, intraplantar injection to the injured paw, or a transdermal solution on the injured paw. Dose–response curves for each route of administration and each nociceptive test were generated, and analgesic synergy was assessed by isobolographic analysis. Results In naïve animals, the loperamide–oxymorphindole combination ED50 value was 10 times lower than the theoretical additive ED50 value whether given systemically or locally. In inflamed animals, the combination was 150 times more potent systemically, and 84 times more potent locally. All combinations showed statistically significant synergy when compared to the theoretical additive values, as verified by isobolographic analysis. The antihyperalgesia was ablated by a peripherally-restricted opioid antagonist. Conclusions From these data we conclude that the loperamide–oxymorphindole combination synergistically reverses complete Freund’s adjuvant–induced inflammatory hyperalgesia. The authors also conclude that this interaction is mediated by opioid receptors located in the peripheral nervous system.

Sign in / Sign up

Export Citation Format

Share Document